Cloxazolam

Jump to: navigation, search
Cloxazolam
Cloxazolam Wiki Str.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  •  ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life65 Hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H14Cl2N2O2
Molar mass349.2
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Cloxazolam

Articles

Most recent articles on Cloxazolam

Most cited articles on Cloxazolam

Review articles on Cloxazolam

Articles on Cloxazolam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cloxazolam

Images of Cloxazolam

Photos of Cloxazolam

Podcasts & MP3s on Cloxazolam

Videos on Cloxazolam

Evidence Based Medicine

Cochrane Collaboration on Cloxazolam

Bandolier on Cloxazolam

TRIP on Cloxazolam

Clinical Trials

Ongoing Trials on Cloxazolam at Clinical Trials.gov

Trial results on Cloxazolam

Clinical Trials on Cloxazolam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cloxazolam

NICE Guidance on Cloxazolam

NHS PRODIGY Guidance

FDA on Cloxazolam

CDC on Cloxazolam

Books

Books on Cloxazolam

News

Cloxazolam in the news

Be alerted to news on Cloxazolam

News trends on Cloxazolam

Commentary

Blogs on Cloxazolam

Definitions

Definitions of Cloxazolam

Patient Resources / Community

Patient resources on Cloxazolam

Discussion groups on Cloxazolam

Patient Handouts on Cloxazolam

Directions to Hospitals Treating Cloxazolam

Risk calculators and risk factors for Cloxazolam

Healthcare Provider Resources

Symptoms of Cloxazolam

Causes & Risk Factors for Cloxazolam

Diagnostic studies for Cloxazolam

Treatment of Cloxazolam

Continuing Medical Education (CME)

CME Programs on Cloxazolam

International

Cloxazolam en Espanol

Cloxazolam en Francais

Business

Cloxazolam in the Marketplace

Patents on Cloxazolam

Experimental / Informatics

List of terms related to Cloxazolam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cloxazolam[1] (marketed under brand name Sepazon, Olcadil (Brazil, Portugal and Spain), Akton (Belgium), Lubalix (Switzerland) is a drug which is a benzodiazepine derivative.[2] Cloxazolam is metabolised into the active metabolite chlordesmethyldiazepam (delorazepam).[3] It possesses anxiolytic,[4] anticonvulsant,[5] hypnotic,[6] sedative[7] and skeletal muscle relaxant properties.[8]

Indications

Cloxazolam's main use is as an anti-anxiety drug.[9]

Side effects

An increased heart rate may occur as an adverse effect of cloxazolam.[10]

Pharmacology

The pharmacological effects of cloxazolam are a result of mainly its active metabolites, thus cloxazolam is a prodrug. The main site of action of cloxazolam and its active metabolites are the benzodiazepine receptor.[11]

The pharmacological actions of benzodiazepines at the GABAa receptor are similar to those of neurosteroids. Neuroactive steroids are positive allosteric modulators of the GABAa receptor, enhancing GABA function and in turn have effects on mood and other functions. Many benzodiazepines (diazepam, medazepam, estazolam, temazepam, flunitrazepam and nitrazepam) potently inhibit the enzymes involved in the metabolism of neurosteroids. The tetrahydroxazole ring that cloxazolam and oxazolam have decreases the inhibitory potency of benzodiazepines on neurosteroids. Thus there could be subtle differences between cloxazolam and other benzodiazepines.[12] However, because the parent prodrugs of cloxazolam and oxazolam were tested rather than the active metabolites, this is purely speculative.

See also

References

  1. DE Patent 1817923
  2. "Benzodiazepine Names". non-benzodiazepines.org.uk. Retrieved 2008-12-29.
  3. Oliveira-Silva, D.; Oliveira, CH.; Mendes, GD.; Galvinas, PA.; Barrientos-Astigarraga, RE.; De Nucci, G. (Dec 2009). "Quantification of chlordesmethyldiazepam by liquid chromatography-tandem mass spectrometry: application to a cloxazolam bioequivalence study". Biomed Chromatogr. 23 (12): 1266–75. doi:10.1002/bmc.1249. PMID 19488979.
  4. Kamioka, T.; Nakayama, I.; Akiyama, S.; Takagi, H. (Mar 1977). "Effects of oxazolam, cloxazolam, and CS-386, new anti-anxiety drugs, on socially induced suppression and aggression in pairs of monkeys". Psychopharmacology (Berl). 52 (1): 17–23. doi:10.1007/BF00426594. PMID 15296.
  5. Ito, M.; Miyajima, T.; Fujii, T.; Okuno, T. (Feb 2004). "Cloxazolam treatment for patients with intractable epilepsy". Pediatr Neurol. 30 (2): 111–4. doi:10.1016/j.pediatrneurol.2003.07.004. PMID 14984903.
  6. Inoue, H.; Maeno, Y.; Iwasa, M.; Matoba, R.; Nagao, M. (Sep 2000). "Screening and determination of benzodiazepines in whole blood using solid-phase extraction and gas chromatography/mass spectrometry". Forensic Sci Int. 113 (1–3): 367–73. doi:10.1016/S0379-0738(00)00226-7. PMID 10978650.
  7. Brisse, B.; Tetsch, P.; Toye, A. (1980). "[Clinical study on stress protective action of cloxazolam in jaw surgery in double blind comparison to placebo (author's transl)]". Arzneimittelforschung. 30 (4): 679–82. PMID 6104969.
  8. Ansseau, M.; von Frenckell, R. (1990). "Controlled comparison of two anxiolytic benzodiazepines, cloxazolam and bromazepam". Neuropsychobiology. 24 (1): 25–9. doi:10.1159/000119038. PMID 1983433.
  9. Fischer-Cornelssen, KA. (1981). "Multicenter trials and complementary studies of cloxazolam, a new anxiolytic drug". Arzneimittelforschung. 31 (10): 1757–65. PMID 6119092.
  10. Boucsein, W.; Wendt-Suhl, G. (Mar 1982). "[Psychological and physiological effects of cloxazolam and diazepam under anxiety-evoking and control conditions on healthy subjects (author's transl)]". Pharmacopsychiatria. 15 (2): 48–56. doi:10.1055/s-2007-1019508. PMID 6123123.
  11. Nakatsuka, I.; Shimizu, H.; Asami, Y.; Katoh, T.; Hirose, A.; Yoshitake, A. (Jan 1985). "Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity". Life Sci. 36 (2): 113–9. doi:10.1016/0024-3205(85)90089-X. PMID 2857046.
  12. Usami N; Yamamoto T; Shintani S; Ishikura S; Higaki Y; Katagiri Y; Hara A. (Apr 2002). "Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines" (pdf). Biol Pharm Bull. 25 (4): 441–5. doi:10.1248/bpb.25.441. PMID 11995921.

External links


Template:GABAAR PAMs


Linked-in.jpg